These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 20199979

  • 1. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
    Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G.
    Clin Lung Cancer; 2010 Mar 01; 11(2):126-31. PubMed ID: 20199979
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ.
    J Clin Oncol; 2009 Apr 20; 27(12):2038-45. PubMed ID: 19307503
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M.
    Cancer Chemother Pharmacol; 2012 Aug 20; 70(2):271-6. PubMed ID: 22752216
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD.
    J Clin Oncol; 2009 Jul 10; 27(20):3284-9. PubMed ID: 19433684
    [Abstract] [Full Text] [Related]

  • 5. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M.
    Clin Lung Cancer; 2013 May 10; 14(3):215-23. PubMed ID: 23332288
    [Abstract] [Full Text] [Related]

  • 6. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
    Xu Y, Ma S, Ji Y, Sun X, Jiang H, Chen J, Du X, Zheng Y, Qiu G.
    Lung Cancer; 2011 Jun 10; 72(3):327-32. PubMed ID: 21056507
    [Abstract] [Full Text] [Related]

  • 7. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
    Kubota K, Niho S, Enatsu S, Nambu Y, Nishiwaki Y, Saijo N, Fukuoka M.
    J Thorac Oncol; 2009 Dec 10; 4(12):1530-6. PubMed ID: 19755925
    [Abstract] [Full Text] [Related]

  • 8. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
    Malhotra B, Evans T, Weiss J, Eaby B, Stonehouse-Lee S, Sherry V, Langer CJ.
    Clin Lung Cancer; 2010 May 10; 11(3):192-7. PubMed ID: 20439196
    [Abstract] [Full Text] [Related]

  • 9. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.
    Gridelli C, Brodowicz T, Langer CJ, Peterson P, Islam M, Guba SC, Moore P, Visseren-Grul CM, Scagliotti G.
    Clin Lung Cancer; 2012 Sep 10; 13(5):340-6. PubMed ID: 22266043
    [Abstract] [Full Text] [Related]

  • 10. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
    Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF.
    J Clin Oncol; 2012 Dec 20; 30(36):4501-7. PubMed ID: 23109689
    [Abstract] [Full Text] [Related]

  • 11. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.
    Lancet Oncol; 2012 Mar 20; 13(3):247-55. PubMed ID: 22341744
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A.
    Lung Cancer; 2012 Oct 20; 78(1):92-9. PubMed ID: 22889494
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
    Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN, Murad A, Franke FA, Precivale M, Araujo LH, Baldotto CS, Vieira FM, Small IA, Ferreira CG, Lilenbaum RC.
    J Clin Oncol; 2013 Aug 10; 31(23):2849-53. PubMed ID: 23775961
    [Abstract] [Full Text] [Related]

  • 17. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
    Galetta D, Pisconti S, Cinieri S, Pappagallo GL, Gebbia V, Borsellino N, Maiello E, Rinaldi A, Montrone M, Rizzo P, Marzano N, Sasso N, Febbraro A, Colucci G.
    Clin Lung Cancer; 2011 Nov 10; 12(6):402-6. PubMed ID: 21831718
    [Abstract] [Full Text] [Related]

  • 18. Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.
    Gervais R, Robinet G, Clément-Duchêne C, Denis F, El Kouri C, Martin P, Chouaki N, Bourayou N, Morère JF.
    Lung Cancer; 2013 May 10; 80(2):185-90. PubMed ID: 23434351
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G.
    J Clin Oncol; 2011 Aug 01; 29(22):2965-71. PubMed ID: 21709202
    [Abstract] [Full Text] [Related]

  • 20. [Pemetrexed monotherapy in previously treated patients with advanced non small cell lung cancer; differences by histology. Our experience].
    Pistillucci G, Sciacca V, Ciorra A, Di Palma T, Calabretta F, Lugini A, Rossi R, D'Aprile M, Veltri E.
    Recenti Prog Med; 2012 Feb 01; 103(2):62-5. PubMed ID: 22430749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.